INCY Stock Analysis: Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its
- Latest close
- $124.82
- 20-day change
- +0.36%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Incyte Corporation moved +0.36% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $5.1B revenue · $1.3B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 5.9/6, while Value is the lowest at 4.4/6. Scores are comparative research signals, not forecasts.